罗欣药业集团股份有限公司 董事会审计委员会对会计师事务所 2023 年度履职情况评估 及履行监督职责情况的报告 1、基本信息 | 事务所名称 | | | 天健会计师事务所（特殊普通合伙） | | | | | --- | --- | --- | --- | --- | --- | --- | | 成立日期 | 2011 年 7 18 日 | 月 | | 组织形式 | | 特殊普通合伙 | | 注册地址 | 浙江省杭州市西湖区灵隐街道西溪路 | | | | 号 128 | | | 首席合伙人 | 王国海 上年末合伙人数量 | | | | | 238 人 | | 上年末执业 | 注册会计师 | | | | | 人 2,272 | | 人员数量 | 签署过证券服务业务审计报告的注册会计师 | | | | | 836 人 | | 年（经 2023 | 业务收入总额 | | | 亿元 34.83 | | | | 审计）业务 | 审计业务收入 | | | 30.99 亿元 | | | | 收入 | 证券业务收入 | | | 亿元 18.40 | | | | | 客户家数 | | | 675 家 | | | | 年 度 20 ...

罗欣药业集团股份有限公司 2023 年度独立董事述职报告 作为罗欣药业集团股份有限公司（以下简称"公司"）的独立董事，在 2023 年度工作中，本人严格按照《中华人民共和国公司法》《深圳证券交易所股票上 市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》《上市公司独立董事管理办法》等法律、法规、规范性文件和《罗欣药业 集团股份有限公司章程》（以下简称"《公司章程》"）规定和要求，恪尽职守、 勤勉尽责地履行独立董事职责，维护公司和股东尤其是中小股东的合法权益。现 将本人 2023 年度履职情况报告如下： 一、基本情况 本人许霞，1972 年出生，中国国籍，无境外永久居留权，本科学历，高级 会计师、注册会计师、注册税务师、国际注册内部审计师。1990 年 7 月至 1993 年 12 月，任江阴职工大学校办厂财务科长。1994 年 1 月至 1999 年 12 月，任江 阴民用建筑安装工程公司财务经理。2000 年 1 月至 2011 年 12 月，先后任江苏 中达新材料集团股份有限公司财务经理、财务总监助理、事业部副总经理。2012 年 1 月至 2019 年 3 月，任华达汽车 ...

2023年度董事会工作报告 2023 年度，罗欣药业集团股份有限公司（以下简称"公司"）董事会严格按 照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《深圳证券交易所股票上市规则》《上市公司自律监管 指引第 1 号——主板上市公司规范运作》等相关法律、法规、规范性文件及《罗 欣药业集团股份有限公司章程》（以下简称"《公司章程》"）、《董事会议事规则》 等公司制度的规定，勤勉尽责地开展各项工作，积极推进董事会各项决议的实施， 不断规范公司法人治理结构，确保董事会科学决策和规范运作，切实履行股东大 会赋予的董事会职责，严格执行股东大会各项决议，有效地维护和保障了公司和 全体股东的利益。现将董事会 2023 年主要工作情况汇报如下： 一、报告期内公司管理经营情况 报告期内，公司在董事会的领导和管理层及全体员工的共同努力下，坚持"一 个罗欣，统一行动"，为传递健康的使命而努力奋斗。2023 年度，公司实现营业 收入 23.64 亿元，比去年同期下降了 34.11%；归属于上市公司股东的净利润为 -6.61 亿元，比去年同期增加了 46.03%；归属于上市公司 ...

Business Transformation - The company reported a significant transformation in its main business, shifting from manufacturing pumps to pharmaceutical products after acquiring 99.65% of Shandong Luoxin in 2019[21]. - The company’s main business now focuses on the research, production, and sales of pharmaceutical products[21]. - The company has undergone a change in its registered address in 2023, moving from Zhejiang to Shandong[17]. Financial Performance - The company's operating revenue for 2023 was ¥2,363,867,226.54, a decrease of 34.11% compared to ¥3,587,547,040.11 in 2022[24]. - The net profit attributable to shareholders for 2023 was ¥661,138,090.85, representing a 46.03% increase from ¥1,225,541,305.85 in 2022[24]. - The net cash flow from operating activities improved significantly to ¥466,888,340.77, a 149.72% increase from a negative cash flow of ¥939,126,902.89 in 2022[24]. - The basic earnings per share for 2023 was -¥0.61, an improvement of 29.07% from -¥0.86 in 2022[24]. - Total assets at the end of 2023 were ¥5,117,407,330.00, a decrease of 36.97% from ¥8,107,824,380.00 in 2022[23]. - The net assets attributable to shareholders decreased by 22.20% to ¥2,469,901,450.00 in 2023 from ¥3,174,106,040.00 in 2022[23]. - The company experienced a net loss attributable to shareholders of ¥431,626,841.10 in Q4 2023, following losses in previous quarters[28]. - Non-recurring gains and losses for 2023 totaled -¥22,285,473.56, compared to ¥223,307,183.79 in 2022[30]. - The company has indicated uncertainty regarding its ability to continue as a going concern, as the net profit before and after deducting non-recurring gains and losses has been negative for the last three accounting years[24]. Industry Overview - The pharmaceutical manufacturing industry in China achieved revenue of CNY 25,205.7 billion in 2023, a decrease of 3.7% compared to the same period in 2022, with total profits declining by 15.1% to CNY 3,473.0 billion[34]. - The overall revenue for the pharmaceutical and biotechnology sector's listed companies reached CNY 18,770.8 billion in the first three quarters of 2023, an increase of 1.8% year-on-year, while net profit attributable to shareholders fell by 17.7% to CNY 1,550.2 billion[35]. Product Development and Innovation - The company achieved a breakthrough with the approval of its first Class 1 innovative drug, Tegoprazan tablets, in 2022, and received additional indications for duodenal ulcers in 2023[44]. - The company is focusing on refined management to optimize fixed expenditures and effectively reduce costs[51]. - The company is enhancing operational efficiency to address industry and market challenges, aiming for a balance between resource allocation and financial performance[51]. - The company is committed to providing affordable clinical medications through its generic drug development efforts[46]. - The company has established a comprehensive production management system to ensure efficient operations from R&D to commercialization[48]. - The company is expanding its market presence through direct sales teams and partnerships with strong regional distributors[50]. - The company has made significant progress in multiple generic drug development projects, including the approval of new generics such as Rivaroxaban tablets and Urapidil injection, with Urapidil injection winning a bid in the national procurement in November 2023[52]. Governance and Compliance - The company’s financial report is guaranteed to be true, accurate, and complete by its board and management, ensuring accountability[5]. - The company emphasizes transparent information disclosure, utilizing multiple channels to communicate with investors and ensure equal access to information[127]. - The company has established a complete and standardized operational system for research and development, procurement, production, quality control, and sales, demonstrating its capability to operate independently in the market[128]. - The company has a clear strategy for maintaining independence in its operations, which is crucial for its long-term growth and stability[128]. - The company has established a comprehensive corporate governance structure, including a board of directors, supervisory board, and various specialized committees[165]. Environmental Responsibility - The company strictly adheres to environmental protection laws and regulations, including the Environmental Protection Law of the People's Republic of China and various local standards[172]. - The company has implemented strict emission standards for various pollutants, ensuring compliance with local and national regulations[172]. - The company has established a solid waste management system, including storage for general and hazardous waste, ensuring proper disposal[183]. - The company has invested in pollution control technologies to meet stringent environmental regulations, reflecting its commitment to sustainability[177]. Employee Development and Social Responsibility - The company has established a comprehensive salary incentive policy that combines business performance with individual contributions, aiming to enhance employee motivation[158]. - The company organized 45 talent development activities in 2023, with a total of 4,146 participants, reflecting its commitment to employee growth and development[192]. - The company donated drugs worth 1 million yuan and contributed 650,000 yuan to various charitable organizations, demonstrating its commitment to social responsibility[193]. - The company actively participated in rural revitalization efforts, focusing on education, healthcare, and infrastructure to break the cycle of poverty[194]. Future Outlook - The company expects steady and rapid growth in the pharmaceutical industry driven by aging population and increased health awareness[103]. - The company plans to enhance its product offerings and expand market presence in response to growing demand for high-quality pharmaceutical products[103]. - In 2024, the company plans to strengthen innovation R&D, expand market efforts, and improve operational capabilities to ensure steady development[106].

目 录 本报告仅供罗欣药业公司年度报告披露时使用，不得用作任何其他目的。我 们同意将本报告作为罗欣药业公司年度报告的必备文件，随同其他文件一起报送 并对外披露。 为了更好地理解罗欣药业公司 2023 年度营业收入扣除情况，扣除情况表应 当与已审的财务报表一并阅读。 二、管理层的责任 一、关于营业收入扣除情况的专项核查意见………………………第 1—2 页 二、2023 年度营业收入扣除情况表…………………………………第 3—5 页 | 三、附件………………………………………………………………第 | 6—9 | 页 | | --- | --- | --- | | （一）本所营业执照复印件……………………………………… | 第 6 | 页 | | （二）本所执业证书复印件……………………………………… | 第 7 | 页 | | （三）注册会计师执业证书复印件……………………………第 | 8—9 | 页 | 关于营业收入扣除情况的专项核查意见 天健审〔2024〕6-250 号 罗欣药业集团股份有限公司全体股东： 我们接受委托，审计了罗欣药业集团股份有限公司（以下简称罗欣药业公司） 2023 年度财务报表，包括 20 ...

1 罗欣药业集团股份有限公司 第一条 为适应公司战略发展需要，提高公司发展规划水平，健全投资决策 程序，加强决策科学性，提高重大投资决策的效益和决策的质量， 完善公司治理结构，根据《中华人民共和国公司法》《深圳证券交易 所上市公司自律监管指引第 1 号——主板上市公司规范运作》《上市 公司治理准则》《罗欣药业集团股份有限公司公司章程》（以下简称 "公司章程"）及其他有关规定，公司设立董事会战略委员会，并制 定本细则。 第二条 董事会战略委员会是董事会设立的专门工作机构，主要负责对公司 长期发展战略和重大投资决策进行研究并提出建议。 第三条 战略委员会至少由三名董事组成。 第四条 战略委员会委员由董事长、二分之一以上独立董事或者三分之一以 上的全体董事提名，并由董事会选举产生。 第五条 战略委员会设委员会主任委员一名，由董事长或总经理担任。 第六条 战略委员会任期与董事会任期一致，委员任期届满，连选可以连任。 期间如有委员不再担任公司董事职务，自动失去委员资格，并由委 员会根据上述第三至第五条规定补足委员人数。 第七条 董事任期届满未及时改选，在改选出的董事就任前，原作为战略委 员会委员的董事仍应当依照法律、行 ...

2023 年度独立董事述职报告 作为罗欣药业集团股份有限公司（以下简称"公司"）的独立董事，在 2023 年度工作中，本人严格按照《中华人民共和国公司法》《深圳证券交易所股票上 市规则》（以下简称"《股票上市规则》"）、《深圳证券交易所上市公司自律 监管指引第 1 号——主板上市公司规范运作》《上市公司独立董事管理办法》等 法律、法规、规范性文件和《罗欣药业集团股份有限公司章程》（以下简称"《公 司章程》"）的规定，认真履行独立董事职责，及时出席相关会议，认真审议会 议议案，对公司重大事项发表了审慎、公正、客观的专业性意见，充分发挥独立 董事及各专门委员会委员的作用，切实维护了公司及股东特别是中小股东的合法 权益。现将本人 2023 年度履职情况报告如下： 罗欣药业集团股份有限公司 一、基本情况 本人武志昂，1966 年生，中国国籍，无境外永久居留权，博士研究生学历， 教授、主任药师。1989 年 7 月至 2009 年 1 月，历任国家药品监督管理局药品审 评中心主任助理、国家食品药品监督管理局药品评价中心及国家药品不良反应监 测中心副主任；2009 年 1 月至 2018 年 4 月，历任沈阳药科大学工商 ...

证券代码：002793 股票简称：罗欣药业 公告编号：2024-018 （二）审议通过《关于 2023 年度内部控制评价报告的议案》 罗欣药业集团股份有限公司 第五届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、 监事会会议召开情况 2024 年 4 月 25 日，罗欣药业集团股份有限公司（以下简称"公司"）第五 届监事会第七次会议在山东省临沂高新技术产业开发区罗七路管理中心三楼会 议室和上海市浦东新区前滩中心会议室以现场表决和通讯表决相结合的方式召 开。会议通知已于 2024 年 4 月 15 日以电话、专人送达、电子邮件等方式发出。 本次会议应出席监事 3 名，实际出席监事 3 名。监事会主席宋良伟女士主持了本 次会议。本次监事会按照《中华人民共和国公司法》（以下简称"《公司法》"）及 其他法律、法规和《罗欣药业集团股份有限公司章程》（以下简称"《公司章程》"） 的规定召开，会议程序合法有效。 二、 监事会会议审议情况 （一）审议通过《关于 2023 年度监事会工作报告的议案》 2023 年，公司监事会严格按照相关法律、法规 ...

罗欣药业集团股份有限公司 会计师事务所选聘制度 第一章 总 则 第一条 为规范罗欣药业集团股份有限公司（以下简称"公司"）选聘（含 续聘、改聘，下同）执行年报审计业务的会计师事务所的有关行为，提高财务信 息质量，切实维护股东利益，根据《中华人民共和国公司法》《中华人民共和国 证券法》《国有企业、上市公司选聘会计师事务所管理办法》和《罗欣药业集团 股份有限公司章程》（以下简称"《公司章程》"）等有关规定，特制定本制度。 第二条 选聘会计师事务所，是指公司根据相关法律法规要求，聘任会计师 事务所对公司财务会计报告予以审计，并出具审计报告的行为。 公司选聘执行年度财务报表审计业务的会计师事务所，应当遵照本制度的规 定，履行选聘程序，披露相关信息。选聘其他专项审计业务的会计师事务所，视 重要性程度可参照本制度执行。 第三条 公司选聘会计师事务所应当由董事会审计委员会（以下简称"审计 委员会"）审议同意后，提交董事会审议、并由股东大会决定。公司不得在董事 会、股东大会审议批准前聘请会计师事务所开展审计业务。 第四条 公司控股股东、实际控制人不得向公司指定会计师事务所，不得干 预公司审计委员会、董事会及股东大会独立履行审 ...

Financial Performance - The company's revenue for Q1 2024 was ¥688,728,623.11, representing a 3.97% increase compared to ¥662,426,362.85 in the same period last year[4]. - The net loss attributable to shareholders decreased to ¥36,661,627.21, a 59.37% improvement from a loss of ¥90,235,051.14 in Q1 2023[4]. - The net profit for the first quarter of 2024 was -49,632,892.41 CNY, compared to -103,502,385.34 CNY in the same period last year, showing an improvement of approximately 52%[20]. - The company reported a total comprehensive income of -48,314,377.49 CNY for the first quarter, compared to -106,871,684.61 CNY in the same quarter last year, indicating a 55% improvement[20]. - Basic and diluted earnings per share were both -0.03 CNY, compared to -0.08 CNY in the previous year[20]. Cash Flow - The net cash flow from operating activities was negative at ¥96,079,755.91, a significant decline of 457.83% compared to a positive cash flow of ¥26,850,638.73 in the previous year[4]. - The company reported a significant decrease in cash received from operating activities, down 71.90% to ¥18,325,259.55 from ¥65,209,714.51 in Q1 2023[9]. - The net cash flow from investing activities was 9,197,783.26 CNY, a decrease from 584,960,373.21 CNY in the previous year[21]. - The net cash flow from financing activities was 84,032,259.64 CNY, compared to -797,934,844.53 CNY in the same period last year, indicating a significant turnaround[22]. Assets and Liabilities - The total assets at the end of Q1 2024 were ¥5,117,183,197.47, showing no significant change from ¥5,117,407,332.82 at the end of the previous year[4]. - Total current assets rose to ¥2,111,895,131.73, up from ¥2,067,511,343.63, marking an increase of 2.1%[16]. - Total liabilities increased to ¥2,693,086,853.36 from ¥2,544,998,012.34, representing a growth of 5.8%[18]. - The company’s total equity attributable to shareholders decreased by 5.48% to ¥2,334,555,189.88 from ¥2,469,901,453.15 at the end of the previous year[4]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,083[11]. - The largest shareholder, Shandong Luoxin Holdings, holds 21.79% of shares, totaling 209,829,196 shares[11]. - The company has repurchased a total of 26,027,861 shares, representing 2.39% of the total share capital[14]. - The repurchase was conducted at a total cost of approximately RMB 99.99 million, with a maximum price of RMB 4.21 per share[14]. - The company plans to use the repurchased shares for employee stock ownership plans or equity incentives[14]. - The top ten shareholders include both domestic and foreign entities, with significant stakes held by natural persons[11]. - The total number of shares held by the top ten unrestricted shareholders is 236,955,520 shares[11]. - The company has set a repurchase fund amounting to no less than RMB 50 million and no more than RMB 100 million[13]. - The repurchase plan is valid for 12 months from the board's approval date[13]. Research and Development - Research and development expenses decreased by 60.53% to ¥15,349,082.71 from ¥38,888,009.55 in Q1 2023, indicating reduced investment in R&D[9]. - Research and development expenses were ¥15,349,082.71, down 60.5% from ¥38,888,009.55 in the previous period[19]. Inventory and Other Assets - Inventory decreased to ¥419,729,072.59 from ¥455,611,306.50, a reduction of 7.9%[16]. - Non-current assets totaled ¥3,005,288,065.74, down from ¥3,049,895,989.19, a decrease of 1.5%[17]. - Cash and cash equivalents increased to ¥723,870,325.69 from ¥692,899,478.54, a rise of 4.5%[16]. - Cash and cash equivalents at the end of the period were 578,525,332.22 CNY, down from 642,998,306.21 CNY at the end of the previous year[22]. Operating Costs - Total operating costs decreased to ¥737,869,165.84 from ¥752,691,953.36, reflecting a reduction of 2.0%[19]. - The company generated 656,674,687.35 CNY from sales of goods and services, a slight decrease from 666,158,367.11 CNY year-over-year[21].